An invited Guest Editorial entitled “Give Cas a Chance,” by Fyodor Urnov, PhD, Director of Technology & Translation at the ...

An editorial by Fyodor Urnov lays out the urgent case for major reform in the regulatory appraisal of clinical therapies involving CRISPR gene therapies.

The FDA sought the independent panel’s advice, in part, because this would be the first time the FDA would approve a treatment that uses CRISPR technology, but Dr. Fyodor Urnov, a professor in ...

The day’s first expert witness was Fyodor Urnov, a University of California, Berkeley professor and gene editing pioneer (who has consulted for Vertex). Urnov said that laboratory techniques for ...

"This is an exceptionally ambitious and important trial," said Fyodor Urnov, professor of molecular and cell biology at UC-Berkeley and a gene editor at IGI, in an email. "It would be good to know ...

Other barriers include the traditional drug development regulatory framework and the business model, argues Fyodor Urnov, director of technology and translation at the Innovative Genomics Institute.

This story first appeared in Adam’s Biotech Scorecard, a subscriber-only newsletter. STAT+ subscribers can sign up here to get it delivered to their inbox. The deep financial restructuring ...

Fyodor Dostoevsky was anything but a serene figure. He wrestled with faith, doubt and his own flawed humanity, translating those struggles into novels that described the chaos and contradictions ...